RVL Pharmaceuticals Company Description

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.

It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.

The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.

RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVL Pharmaceuticals plc

Country	Ireland
Industry	Biotechnology
Sector	Healthcare
Employees	125
CEO	Brian Markison

Contact Details

Address: 400 Crossing Boulevard Bridgewater, 08807 United States
Phone	908 809 1300
Website	rvlpharma.com

Stock Details

Ticker Symbol	RVLPQ
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	IE00BF2HDL56
SIC Code	2834

Key Executives

Name	Position
Brian A. Markison	Chairman, President, Chief Executive Officer and Principal Financial Officer
James D. Schaub	Executive Vice President and Chief Operating Officer
Christopher A. Klein J.D.	General Counsel
Michael J. DePetris	Principal Accounting Officer
Jarret Miller	Executive Vice President of Human Resources
Scott Schroppe	Secretary